Cresanto Global Peer Comparison

BSE: 531207

₹5.12

₹0.00 (0.00%)

As on 24-Aug-2026IST

Market cap

₹2 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

-0.7

Div. Yield

0 %

Edit

	Cresanto Global	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Market cap (₹ Cr)	2	21,894	19,021	17,760	18,168
Revenue (₹ Cr)	0	2,570	2,287	2,432	3,230
Net Profit (₹ Cr)	-0.40	735.15	678.07	169.62	666.92
Net Margin (%)	-521.05	26.88	28.10	6.90	20.60
RoE (%)	--	19.16	19.73	20.76	18.75
Price to Earnings	--	29.78	28.59	104.70	28.21
Price-To-Book	-0.71	4.97	5.05	19.64	4.49

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Cresanto Global	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Operating Revenue	0.05	2,519.65	1,937.47	2,275.58	2,893.64
Total Income	0.08	2,707.60	2,033.90	2,304.07	2,912.00
Total Expenditure	0.35	1,615.47	1,290.54	2,013.55	1,876.44
EBITDA	-0.29	904.18	646.93	262.03	1,017.20
Depreciation	0.00	57.73	65.96	28.58	315.46
EBIT	-0.29	846.45	580.97	233.45	701.74
Interest	0.16	9.57	0.61	4.49	231.29
Other Income	0.02	187.95	96.43	28.49	18.36
Exceptional Items	--	-49.16	--	-5.25	--
Profit before Tax	-0.43	975.67	676.78	252.20	488.87
Provision for Tax	0.00	253.24	135.69	64.68	114.20
Profit after Tax	-0.43	722.43	541.09	187.52	374.67

Liabilities (₹ Cr)

	Cresanto Global	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Shareholder's Funds	-3.02	4,202.90	2,850.49	872.79	2,854.36
Minority Interest	--	--	35.90	--	417.40
Non-Current Liabilities	2.81	19.19	13.24	394.49	2,100.97
Current Liabilities	0.22	627.48	305.99	1,109.50	1,489.55
Total Liabilities	0.01	4,921.88	3,207.85	2,414.58	6,862.28

Assets (₹ Cr)

	Cresanto Global	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Non-Current Assets	--	1,046.35	1,071.67	509.16	5,531.13
Current Assets	0.01	3,803.22	2,133.95	1,859.88	1,331.15
Total Assets	0.01	4,921.88	3,207.85	2,414.58	6,862.28
Total Debt*	2.81	2.50	0.55	0.00	2,421.66
Net Current Assets	-0.21	3,175.74	1,827.96	750.38	-158.40
Contingent Liabilities	--	370.49	0.64	121.23	64.29

Cashflow (₹ Cr)

	Cresanto Global	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Cash From Operating Activities	-0.27	967.57	432.37	-15.14	1,065.01
Cash Flow from Investing Activities	0.44	-561.67	-334.73	18.69	-79.97
Cash from Financing Activities	-0.16	-798.31	-38.32	-91.97	-881.32
Net Cash Inflow / Outflow	0.01	-392.41	59.32	-88.42	103.72

Ratios

Profitability Ratios

	Cresanto Global	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
ROCE (%)	0.00	23.39	26.22	31.24	13.59
ROE (%)	0.00	17.16	21.72	23.02	13.81
ROA (%)	-2,099.02	14.91	18.37	8.90	5.48
EBIT Margin (%)	-503.90	43.34	38.37	12.77	35.79
Net Margin (%)	-569.18	26.68	26.60	8.14	12.87
Cash Profit Margin (%)	-798.33	29.72	31.33	9.47	23.22

Growth Ratios

	Cresanto Global	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Revenue Growth (%)	--	10.45	14.37	32.59	44.02
EBIT Growth (%)	-343.79	19.68	20.21	-1.38	48.22
Net Profit Growth (%)	-138.39	-5.88	17.27	62.02	-5.65
EPS Growth (%)	-138.38	-5.88	17.25	62.02	-10.39
Book Value Growth (%)	-16.63	-0.34	23.77	13.51	10.19

Valuation Ratios

	Cresanto Global	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Price / Earnings	0.00	29.89	28.38	103.45	54.83
Price / Book Value	-0.63	5.14	5.52	22.39	6.78
Dividend Yield (%)	0.00	1.59	0.30	0.46	0.52
EV/EBITDA	-17.28	16.93	19.78	65.23	20.75
Market Cap (₹ Cr)	1.89	21,592.90	15,219.80	19,398.64	19,292.77

Solvency Ratios

	Cresanto Global	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debt to Equity	-0.93	0.00	0.00	0.00	0.85
Short term debt to equity ratio	--	0.00	0.00	--	0.14
Current Ratio	0.04	6.06	6.97	1.68	0.89
Quick Ratio	0.04	5.31	5.88	0.75	0.67
Interest Coverage	-1.71	102.95	1,110.48	57.17	3.11

Operating Efficiency Ratios

	Cresanto Global	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debtors to sales (%)	--	7.22	32.65	9.39	15.85
Asset Turnover	2.63	0.54	0.66	1.08	0.43
Receivable days	0.00	26.06	110.70	31.88	54.07
Inventory Days	0.00	65.95	65.86	126.03	32.16
Payable days	--	81.01	105.88	163.79	140.91
Cash Conversion Cycle	--	11.00	70.68	-5.88	-54.68

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly